-
In category NewsStudying vaccines for pneumococcal disease
FVR – Finnish Vaccine Research has a team of specialists who have studied pneumococcal disease over several decades. In addition to clinical vaccine trials conducted at our ten research clinics, we specialize in phase 4 vaccine effectiveness and safety studies based on real-world data and use national health registers to study the burden of vaccine-preventable […]
-
In category NewsChange of registered official company name
Dear partner, Please note that we have changed our official company name, as registered at the Finnish Patent and Registration Office (PRH). The change means that we have made our former registered auxiliary business name FVR – Finnish Vaccine Research our official primary company name. The business ID and other details remain unchanged. This change […]
-
In category NewsStudying vaccines for CMV (cytomegalovirus)
FVR – Finnish Vaccine Research has a team of specialists who have conducted two major clinical studies of CMV vaccines over several years, enrolling healthy women under 40 years of age. Our track-record of enrolling participants for these studies is good, despite screening criteria that limit the number of qualified participants, such as contact with […]
-
In category NewsWhy partner with FVR – Finnish Vaccine Research in studying vaccines for RSV?
FVR’s unique network of ten clinical vaccine research clinics ensures good capacity and flexibility is available for conducting a successful study. Our expertise covers comprehensive clinical vaccine trials through phases 1-4, including register-based Real-World Evidence studies and large-scale pragmatic field trials, conducted together with healthcare providers. Finland offers an excellent setting for a successful study […]
-
In category News
FVR’s overview of year 2022 has been published
On March 31st 2023, FVR has published an overview of the founding year of the company. You can access the report by clicking the link below. The report includes the following sections: FVR – Finnish Vaccine Research became fully operational on September 1, 2022, when the founding organizations, Tampere University Foundation and the Finnish Institute […]
-
In category NewsGSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
On March 14th, 2023, GSK announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. Invasive meningococcal disease (IMD), a major cause of meningitis and septicaemia, is an uncommon […]
-
In category BlogConducting successful clinical trials for influenza vaccines
Finding more effective vaccines for the constantly moving target of influenza with longer-term immunity is a cause worth pursuing. For example, the mRNA technology opens opportunities to develop and manufacture effective vaccines closer to the flu season, with a better match to the circulating viruses. But what are successful clinical trials made of? Mika Rämet, […]
-
In category NewsModerna announces mRNA-1345, an investigational Respiratory Syncytial Virus (RSV) vaccine, has met primary efficacy endpoints in phase 3 trial in older adults
On January 17th, Moderna announced positive topline data from its Phase 3 trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults. RSV, a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia, causes a particularly large burden of disease in infants and […]
-
In category NewsPfizer announces positive findings in global maternal immunization trial for its RSV vaccine candidate
On November 1st, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its RSV vaccine candidate, RSVpreF, when administered to pregnant participants to help protect their infants from RSV disease after birth. RSV is a contagious virus and a common cause of respiratory […]
-
In category BlogVaccine development thrives – Finland offers unique possibilities
Finland has strong expertise in high-quality vaccine research based on decades of experience. In addition, exceptional national data resources increase the attractiveness of Finland for international research investments. When the overall impact of vaccines is studied on a large scale, in addition to clinical trials aimed at obtaining a license for marketing authorization, important evidence […]
-
In category NewsNew medicine to protect babies and infants from respiratory syncytial virus (RSV) infection
European Medicines Agency (EMA) has recommended a marketing authorisation in the European Union for Beyfortus (nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in newborn babies and infants during their first RSV season. RSV can be serious, especially in infants. It is the most common cause of lower respiratory tract infections, […]
-
In category NewsEvaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
A randomized, placebo-controlled phase 2–3 trial examined the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in 5-to-11-year-old children. 2,268 children were randomly assigned to receive two injections, 21 days apart, of either the BNT162b2 vaccine (at a dose level of 10 μg, selected during phase 1) or […]